指南与共识消化、代谢与肾脏急症重症综合管理与镇静镇痛

COVID-19:胃肠道表现、肝损伤及建议

COVID-19: Gastrointestinal manifestations, liver injury and recommendations.
指南 / 共识 · World J Clin Cases · 2022-01-01
一句话结论COVID-19可累及全胃肠道及肝脏,腹泻等胃肠道受累与住院时间延长、疾病严重度和ICU需求相关;肝硬化、肝细胞癌、自身免疫病或肝移植患者重症风险可能更高。

该文综述COVID-19的胃肠道表现与肝损伤,并检索PubMed、Scopus和Cochran Library探讨慢性胃肠道疾病患者的重症风险及当前治疗建议。肠道和肝脏受累是最常见表现,肠道受累常见症状为腹泻、厌食、恶心/呕吐、腹痛,肝受累表现为转氨酶升高的轻度肝炎。胃肠道受累与住院时间延长、疾病严重度和ICU需求相关。炎症性肠病、肝硬化、肝细胞癌或肝移植患者的治疗和随访在疫情期间受到负面影响;肝硬化、肝细胞癌、自身免疫病或肝移植患者可能重症COVID-19风险更高。诊断或治疗性操作应限于特定情况,非紧急定期随访应使用远程医疗,高危人群不应延迟COVID-19治疗,并应优先接种疫苗。

要点

  • COVID-19累及全胃肠道系统,肠道和肝脏受累是最常见表现,轻症肝炎表现为转氨酶升高。
  • 肠道受累常见症状为腹泻、厌食、恶心/呕吐、腹痛;胃肠道受累与住院时间延长、疾病严重度和ICU需求相关。
  • 肝硬化、肝细胞癌、自身免疫病或肝移植患者可能重症COVID-19风险更高。
  • 诊断或治疗性操作应限于特定情况,非紧急定期随访应使用远程医疗。
  • 高危人群不应延迟COVID-19治疗,并应优先接种COVID-19疫苗。

适用人群与场景

  • COVID-19感染者,尤其是出现胃肠道表现或肝损伤者。
  • 患有慢性胃肠道疾病(如炎症性肠病、肝硬化、肝细胞癌)或接受肝移植的患者。
  • 患有自身免疫病或接受肝移植、可能重症COVID-19风险更高的患者。

处置流程与药物剂量

  • 诊断或治疗性操作应限于特定情况。
  • 非紧急定期患者随访应使用远程医疗。
  • 高危人群不应延迟COVID-19治疗。
  • 高危人群应优先接种COVID-19疫苗。

研究设计与关键结果

  • 截至2021年12月,COVID-19大流行已影响所有国家,约2.7亿患者和500万死亡。
  • 严重急性呼吸综合征冠状病毒2靶向血管紧张素转换酶2受体,该受体常见于人肠道上皮细胞、胆管上皮细胞和肝细胞,所有胃肠道系统器官均受COVID-19感染影响。
  • 肠道和肝脏受累是最常见表现;肠道受累常见症状为腹泻、厌食、恶心/呕吐、腹痛;肝脏受累表现为转氨酶升高的轻度肝炎。
  • 胃肠道受累与住院时间延长、疾病严重度和ICU需求相关。
  • 炎症性肠病、肝硬化、肝细胞癌或肝移植患者的治疗和随访在疫情期间受到负面影响。
  • 肝硬化、肝细胞癌、自身免疫病或肝移植患者可能重症COVID-19风险更高。

证据类型、等级与局限

  • 证据类型:综述;文献检索数据库为PubMed、Scopus和Cochran Library。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 对肝硬化、肝细胞癌、自身免疫病或肝移植患者,应认识到其可能重症COVID-19风险更高。
  • 诊断或治疗性操作应限于特定情况。
  • 非紧急定期随访应使用远程医疗。
  • 高危人群不应延迟COVID-19治疗,并应优先接种COVID-19疫苗。

指南或共识出处

  • World J Clin Cases

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Coronavirus disease 2019 (COVID-19) has caused a pandemic that affected all countries with nearly 270 million patients and 5 million deaths, as of as of December, 2021. The severe acute respiratory syndrome coronavirus 2 virus targets the receptor, angiotensin-converting enzyme 2, which is frequently found in human intestinal epithelial cells, bile duct epithelial cells, and liver cells, and all gastrointestinal system organs are affected by COVID-19 infection. The aim of this study is to review the gastrointestinal manifestations and liver damage of COVID-19 infection and investigate the severe COVID-19 infection risk in patients that have chronic gastrointestinal disease, along with current treatment guidelines. A literature search was conducted on electronic databases of PubMed, Scopus, and Cochran Library, consisting of COVID-19, liver injury, gastrointestinal system findings, and treatment. Liver and intestinal involvements are the most common manifestations. Diarrhea, anorexia, nausea/vomiting, abdominal pain are the most frequent symptoms seen in intestinal involvement. Mild hepatitis occurs with elevated levels of transaminases. Gastrointestinal involvement is associated with long hospital stay, severity of the disease, and intensive care unit necessity. Treatments and follow-up of patients with inflammatory bowel diseases, cirrhosis, hepatocellular carcinoma, or liver transplant have been negatively affected during the pandemic. Patients with cirrhosis, hepatocellular carcinoma, auto-immune diseases, or liver transplantation may have a greater risk for severe COVID-19. Diagnostic or therapeutic procedures should be restricted with specific conditions. Telemedicine should be used in non-urgent periodic patient follow up. COVID-19 treatment should not be delayed in patients at the risk group. COVID-19 vaccination should be prioritized in this group.

来源:World J Clin Cases,查看原文。版权归原作者所有。

参考来源

  1. Ozkurt Z, Çınar Tanrıverdi E. COVID-19: Gastrointestinal manifestations, liver injury and recommendations. World J Clin Cases. 2022. PMID: 35211548. doi:10.12998/wjcc.v10.i4.1140

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。